Stockscreener 앱 받기
4.92
3.72%
-0.19
시간 외 거래:
5.03
0.11
+2.24%
전일 마감가:
$5.11
열려 있는:
$5.15
하루 거래량:
4.11M
Relative Volume:
0.70
시가총액:
$1.47B
수익:
$38.03M
순이익/손실:
$-146.40M
주가수익비율:
-9.4615
EPS:
-0.52
순현금흐름:
$-121.38M
1주 성능:
-4.47%
1개월 성능:
+36.29%
6개월 성능:
+49.09%
1년 성능:
+50.92%
1일 변동 폭
$4.8912
$5.1868
1주일 범위
$4.67
$5.36
52주 변동 폭
$1.8906
$5.82
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
150 W 4TH AVENUE, VANCOUVER
ABCL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.92 | 1.53B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-07 | 재개 | Leerink Partners | Outperform |
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
Why AbCellera Biologics Inc. stock is on top investor watchlistsEntry Plan for Oversold Reversal Stocks Released - beatles.ru
How strong is AbCellera Biologics Inc. company’s balance sheetChart Pattern Trend Scanner With Low Risk - jammulinksnews.com
Does AbCellera Biologics Inc. stock perform well during market downturnsMaximize gains with proven stock analysis - jammulinksnews.com
What is the dividend policy of AbCellera Biologics Inc. stockStay informed with daily expert analysis - jammulinksnews.com
What are analysts’ price targets for AbCellera Biologics Inc. in the next 12 monthsLow Risk Alerts With Proven Results - jammulinksnews.com
When is AbCellera Biologics Inc. stock expected to show significant growthSuperior return velocity - jammulinksnews.com
Should I hold or sell AbCellera Biologics Inc. stock in 2025Get alerts on high-potential stock breakouts - jammulinksnews.com
How does AbCellera Biologics Inc. compare to its industry peersHarness the power of proven investment plans - jammulinksnews.com
Is AbCellera Biologics Inc. stock overvalued or undervaluedGet exclusive market analysis for investors - jammulinksnews.com
How does AbCellera Biologics Inc. generate profit in a changing economyStay ahead with daily expert stock picks - jammulinksnews.com
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - MSN
Why AbCellera Biologics Inc. stock attracts strong analyst attentionBreakout Momentum Alerts - Metal.it
AbCellera’s AI Antibody Platform Excites Investors, Despite Big Risks - Finimize
Is AbCellera Biologics Inc. a good long term investmentConsistent double returns - PrintWeekIndia
AbCellera Biologics Inc. Stock Analysis and ForecastExceptional risk-adjusted gains - PrintWeekIndia
Is AbCellera Biologics Inc. stock a good hedge against inflationSkyrocketing profit margins - jammulinksnews.com
What analysts say about AbCellera Biologics Inc. stockRapid wealth creation - PrintWeekIndia
What drives AbCellera Biologics Inc. stock priceExponential return rates - Autocar Professional
AbCellera: Just Another Biotech Stock (NASDAQ:ABCL) - Seeking Alpha
Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot - MSN
Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength? - MSN
ABCL.O Surges 15.5% Intraday: A Deep Dive Into the Drivers Behind the Sharp Move - AInvest
ABCL Stock Surge: Opportunity or Caution? - StocksToTrade
AbCellera Biologics Stock (ABCL) Opinions on Recent Price Surge - Nasdaq
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday - Benzinga
AbCellera Biologics (ABCL) Surges 18.75% Intraday: What’s Fueling This Biotech Breakout? - AInvest
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
1.06%
자본화:
|
볼륨(24시간):